CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Phase 3
London, United Kingdom and 14 other locations
with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...
Phase 3
London, United Kingdom and 155 other locations
(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...
Phase 3
London, London, City of, United Kingdom and 167 other locations
(CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...
Phase 3
London, United Kingdom and 229 other locations
participants to treat locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEA).T...
Phase 2
London, Greater London, United Kingdom and 48 other locations
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...
Phase 3
London, United Kingdom and 124 other locations
resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease....
Phase 2
London, United Kingdom and 69 other locations
and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma...
Phase 2
London, United Kingdom and 43 other locations
with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma...
Phase 2, Phase 3
London, London, City of, United Kingdom and 159 other locations
An open label single arm phase II trial in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma which is M...
Phase 2
Cambridge, Cambridgeshire, United Kingdom
Clinical trials
Research sites
Resources
Legal